MedTrace Logo

Effects of SQ109 on QTc Interval in Healthy Subjects

NCT01874314 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2014-03-24

No results posted yet for this study

Summary

This will be a single center, open label, crossover study to evaluate the safety and tolerability of multiple dose levels of SQ109.

Conditions

Interventions

DRUG

SQ109

300mg or 450mg of SQ109 administered orally, once daily for 7 days.

OTHER

SQ109 Placebo

Placebo is a round, coated, yellow, unscored tablet. SQ109 Placebo administered orally, once daily for 7 days.

DRUG

Moxifloxacin

400mg of moxifloxacin (positive control) administered orally, once daily for 7 days.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01874314 on ClinicalTrials.gov